Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma.

mutations are ubiquitous in high-grade serous ovarian carcinomas (HGSOC), and the presence of mutation discriminates between high and low-grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a surrogate for mutation but its accuracy has not been established. The objective of this study was to test whether improved methods for p53 IHC could reliably predict mutations independently identified by next generation sequencing (NGS).